Metastasis prevention by targeting the dormant niche

Nature Reviews Cancer

Volumn 15, Issue 4, 2015, Pages 238-247

  Ghajar, Cyrus M ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; ANTINEOPLASTIC AGENT;

BASEMENT MEMBRANE; BREAST CANCER; BREAST TUMOR; CANCER CELL LINE; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE G0 PHASE; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DRUG SENSITIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA STEM CELL; LONG TERM SURVIVAL; METASTASIS; METASTASIS FREE SURVIVAL; MINIMAL RESIDUAL DISEASE; NONHUMAN; PERIVASCULAR NICHE; PRIORITY JOURNAL; REVIEW; STEM CELL NICHE; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; NEOPLASM METASTASIS; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

EID: 84925669716     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3910     Document Type: Review

References (158)

1. Willis, R. A. The Spread of Tumours in the Human Body (J. & A. Churchill, 1934).
2. Schlimok, G. et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc. Natl Acad. Sci. USA 84, 8672-8676 (1987).
3. Cote, R. J. et al. Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease. Am. J. Surg. Pathol. 12, 333-340 (1988).
4. Pantel, K. et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347, 649-653 (1996).
5. Husemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008).
6. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
7. Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793-802 (2005).
8. Cote, R. J., Rosen, P. P., Lesser, M. L., Old, L. J. & Osborne, M. P. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J. Clin. Oncol. 9, 1749-1756 (1991).
9. Mansi, J. L. et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow up. Eur. J. Cancer 27, 1552-1555 (1991).
10. Pantel, K. et al. Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. Eur. J. Cancer 31A, 1627-1632 (1995).
11. Thorban, S. et al. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J. Natl Cancer Inst. 88, 1222-1227 (1996).
12. Schlimok, G. et al. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur. J. Cancer 27, 1461-1465 (1991).
13. Weckermann, D. et al. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J. Urol. 166, 699-703 (2001).
14. Goss, P. E. & Chambers, A. F. Does tumour dormancy offer a therapeutic target? Nature Rev. Cancer 10, 871-877 (2010).
15. Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152-8162 (2004).
16. Uhr, J. W. & Pantel, K. Controversies in clinical cancer dormancy. Proc. Natl Acad. Sci. USA 108, 12396-12400 (2011).
17. Kang, Y. & Pantel, K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 23, 573-581 (2013).
18. Naumov, G. N. et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 62, 2162-2168 (2002).
19. Ghajar, C. M. et al. The perivascular niche regulates breast tumour dormancy. Nature Cell Biol. 15, 807-817 (2013).
20. Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nature Rev. Cancer 7, 834-846 (2007).
21. Gimbrone, M. A. Jr., Leapman, S. B., Cotran, R. S. & Folkman, J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136, 261-276 (1972).
22. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
23. + T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485-498 (2010).
24. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
25. Noltenius, C. & Noltenius, H. Dormant tumor cells in liver and brain. An autopsy study on metastasizing tumors. Pathol. Res. Pract. 179, 504-511 (1985).
26. Naumov, G. N., Folkman, J. & Straume, O. Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin. Exp. Metastasis 26, 51-60 (2009).
27. O'Reilly, M. S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689-692 (1996).
28. Giancotti, F. G. Mechanisms governing metastatic dormancy and reactivation. Cell 155, 750-764 (2013).
29. Sosa, M. S., Bragado, P. & Aguirre-Ghiso, J. A. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nature Rev. Cancer 14, 611-622 (2014).
30. Braun, S. et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 18, 80-86 (2000).
31. Krawczyk, N. et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29, 4019-4024 (2009).
32. Janni, W. et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse - a European pooled analysis. Clin. Cancer Res. 17, 2967-2976 (2011).
33. Naumov, G. N. et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res. Treat. 82, 199-206 (2003).
34. Schmidt-Kittler, O. et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA 100, 7737-7742 (2003).
35. Weckermann, D. et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J. Clin. Oncol. 27, 1549-1556 (2009).
36. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nature Rev. Cancer 13, 714-726 (2013).
37. Weaver, V. M. et al. β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2, 205-216 (2002).
38. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658-1667 (1999).
39. Fridman, R. et al. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc. Natl Acad. Sci. USA 87, 6698-6702 (1990).
40. 1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res. 64, 4514-4522 (2004).
41. Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Med. 5, 662-668 (1999).
42. Boudreau, N., Sympson, C. J., Werb, Z. & Bissell, M. J. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267, 891-893 (1995).
43. Gudjonsson, T. et al. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J. Cell Sci. 115, 39-50 (2002).
44. Lee, E. Y., Parry, G. & Bissell, M. J. Modulation of secreted proteins of mouse mammary epithelial cells by the collagenous substrata. J. Cell Biol. 98, 146-155 (1984).
45. Streuli, C. H. et al. Laminin mediates tissue-specific gene expression in mammary epithelia. J. Cell Biol. 129, 591-603 (1995).
46. Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245 (1997).
47. Weir, M. L. et al. Dystroglycan loss disrupts polarity and β-casein induction in mammary epithelial cells by perturbing laminin anchoring. J. Cell Sci. 119, 4047-4058 (2006).
48. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer 2, 563-572 (2002).
49. Kienast, Y. et al. Real-time imaging reveals the single steps of brain metastasis formation. Nature Med. 16, 116-122 (2010).
50. Butler, J. M., Kobayashi, H. & Rafii, S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nature Rev. Cancer 10, 138-146 (2010).
51. Lammert, E., Cleaver, O. & Melton, D. Induction of pancreatic differentiation by signals from blood vessels. Science 294, 564-567 (2001).
52. Matsumoto, K., Yoshitomi, H., Rossant, J. & Zaret, K. S. Liver organogenesis promoted by endothelial cells prior to vascular function. Science 294, 559-563 (2001).
53. Ding, B. S. et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature 505, 97-102 (2014).
54. Ding, B. S. et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 468, 310-315 (2010).
55. Lindahl, P. et al. Paracrine PDGF-B/PDGF-Rβ signaling controls mesangial cell development in kidney glomeruli. Development 125, 3313-3322 (1998).
56. Tufro, A., Norwood, V. F., Carey, R. M. & Gomez, R. A. Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. J. Am. Soc. Nephrol. 10, 2125-2134 (1999).
57. Ding, B. S. et al. Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell 147, 539-553 (2011).
58. Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507, 323-328 (2014).
59. Ramasamy, S. K., Kusumbe, A. P., Wang, L. & Adams, R. H. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature 507, 376-380 (2014).
60. Louissaint, A. Jr, Rao, S., Leventhal, C. & Goldman, S. A. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 34, 945-960 (2002).
61. Schofield, R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4, 7-25 (1978).
62. Scadden, D. T. Nice neighborhood: emerging concepts of the stem cell niche. Cell 157, 41-50 (2014).
63. Goldman, S. A. & Chen, Z. Perivascular instruction of cell genesis and fate in the adult brain. Nature Neurosci. 14, 1382-1389 (2011).
64. Kiel, M. J. et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121, 1109-1121 (2005).
65. Xiao, Y. et al. Perivascular hair follicle stem cells associate with a venule annulus. J. Invest. Dermatol. 133, 2324-2331 (2013).
66. Christov, C. et al. Muscle satellite cells and endothelial cells: close neighbors and privileged partners. Mol. Biol. Cell 18, 1397-1409 (2007).
67. Crisan, M. et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3, 301-313 (2008).
68. Butler, T. P. & Gullino, P. M. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 35, 512-516 (1975).
69. Klein, C. A. Selection and adaptation during metastatic cancer progression. Nature 501, 365-372 (2013).
70. Calvi, L. M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846 (2003).
71. Zhang, J. et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841 (2003).
72. Rompolas, P., Mesa, K. R. & Greco, V. Spatial organization within a niche as a determinant of stem-cell fate. Nature 502, 513-518 (2013).
73. Tata, P. R. et al. Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature 503, 218-223 (2013).
74. Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481, 457-462 (2012).
75. Vora, A. J., Toh, C. H., Peel, J. & Greaves, M. Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br. J. Haematol. 86, 180-182 (1994).
76. Fischer, J. C. et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc. Natl Acad. Sci. USA 110, 16580-16585 (2013).
77. Shiozawa, Y. et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298-1312 (2011).
78. Stoletov, K. et al. Role of connexins in metastatic breast cancer and melanoma brain colonization. J. Cell Sci. 126, 904-913 (2013).
79. Resovi, A., Pinessi, D., Chiorino, G. & Taraboletti, G. Current understanding of the thrombospondin 1 interactome. Matrix Biol. 37, 83-91(2014).
80. Gao, H. et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150, 764-779 (2012).
81. Lee, J. H. et al. Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis. Cell 156, 440-455 (2014).
82. Kobayashi, A. et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J. Exp. Med. 208, 2641-2655 (2011).
83. Bragado, P. et al. TGF β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling. Nature Cell Biol. 15, 1351-1361 (2013).
84. Morrison, S. J. & Scadden, D. T. The bone marrow niche for haematopoietic stem cells. Nature 505, 327-334 (2014).
85. Shiozawa, Y. et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12, 116-127 (2010).
86. Calabrese, C. et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82 (2007).
87. Charles, N. et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6, 141-152 (2010).
88. Lathia, J. D. et al. Integrin α 6 regulates glioblastoma stem cells. Cell Stem Cell 6, 421-432 (2010).
89. Lathia, J. D. et al. Laminin α 2 enables glioblastoma stem cell growth. Ann. Neurol. 72, 766-778 (2012).
90. Pietras, A. et al. Osteopontin CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14, 357-369 (2014).
91. Zhu, T. S. et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res. 71, 6061-6072 (2011).
92. Hambardzumyan, D. et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 22, 436-448 (2008).
93. Fletcher, J. I., Haber, M., Henderson, M. J. & Norris, M. D. ABC transporters in cancer: more than just drug efflux pumps. Nature Rev. Cancer 10, 147-156 (2010).
94. Lu, J. et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged 1. Cancer Cell 23, 171-185 (2013).
95. Cao, Z. et al. Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell 25, 350-365 (2014).
96. Acharyya, S. et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165-178 (2012).
97. Aird, W. C. Endothelial cell heterogeneity. Cold Spring Harb. Perspect. Med. 2, a006429 (2012).
98. Blankson, J. N., Persaud, D. & Siliciano, R. F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53, 557-593 (2002).
99. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).
100. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
101. Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
102. Richman, D. D. et al. The challenge of finding a cure for HIV infection. Science 323, 1304-1307 (2009).
103. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012).
104. Kulkosky, J. et al. Prostratin: activation of latent HIV 1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98, 3006-3015 (2001).
105. Aguirre Ghiso, J. A., Kovalski, K. & Ossowski, L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104 (1999).
106. Beliveau, A. et al. Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes Dev. 24, 2800-2811 (2010).
107. Kenny, P. A. & Bissell, M. J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J. Clin. Invest. 117, 337-345 (2007).
108. Wang, F. et al. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J. Natl Cancer Inst. 94, 1494-1503 (2002).
109. 1 integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc. Natl Acad. Sci. USA 95, 14821-14826 (1998).
110. El Touny, L. H. et al. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. J. Clin. Invest. 124, 156-168 (2014).
111. Chery, L. et al. Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget. 5, 9939-9951 (2014).
112. Kim, R. S. et al. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS ONE 7, e35569 (2012).
113. Klein, C. A. et al. Combined transcriptome and genome analysis of single micrometastatic cells. Nature Biotech. 20, 387-392 (2002).
114. Welty, C. J. et al. Single cell transcriptomic analysis of prostate cancer cells. BMC Mol. Biol. 14, 6 (2013).
115. MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12, 863-879 (2001).
116. Chen, A. et al. Endothelial cell migration and vascular endothelial growth factor expression are the result of loss of breast tissue polarity. Cancer Res. 69, 6721-6729 (2009).
117. 1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin 1. Cancer Discov. 3, 578-589 (2013).
118. Kang, S. Y. et al. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp 1. Proc. Natl Acad. Sci. USA 106, 12115-12120 (2009).
119. Lawler, J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell. Mol. Med. 6, 1-12 (2002).
120. Jones, F. S. & Rous, P. On the cause of the localization of secondary tumors at points of injury. J. Exp. Med. 20, 404-412 (1914).
121. Psaila, B. & Lyden, D. The metastatic niche: adapting the foreign soil. Nature Rev. Cancer 9, 285-293 (2009).
122. Kaplan, R. N. et al. VEGFR1 positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).
123. Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85-89 (2012).
124. Kim, S. et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102-106 (2009).
125. Oskarsson, T. et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nature Med. 17, 867-874 (2011).
126. Osterberg, L. & Blaschke, T. Adherence to medication. N. Engl. J. Med. 353, 487-497 (2005).
127. Schmidt, D. & Leppik, I. E. (eds) Compliance in Epilepsy (Elsevier, 1988).
128. Davies, C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381, 805-816 (2013).
129. Aft, R. et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 11, 421-428 (2010).
130. Doan, P. L. & Chute, J. P. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia 26, 54-62 (2012).
131. Cogle, C. R. et al. Functional integration of acute myeloid leukemia into the vascular niche. Leukemia 28, 1978-1987 (2014).
132. Colmone, A. et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322, 1861-1865 (2008).
133. Ishikawa, F. et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature Biotech. 25, 1315-1321 (2007).
134. Krause, D. S. et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nature Med. 19, 1513-1517 (2013).
135. Boyerinas, B. et al. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood 121, 4821-4831 (2013).
136. Sipkins, D. A. et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435, 969-973 (2005).
137. Estey, E. et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol. 12, 671-678 (1994).
138. Visani, G. et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia 8, 1842-1846 (1994).
139. Becker, P. S. et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br. J. Haematol. 155, 182-189 (2011).
140. Becker, P. S. Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment. Scientific World Journal 2012, 856467 (2012).
141. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
142. Peled, A. et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283, 845-848 (1999).
143. Norton, L. & Simon, R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat. Rep. 61, 1307-1317 (1977).
144. Trumpp, A., Essers, M. & Wilson, A. Awakening dormant haematopoietic stem cells. Nature Rev. Immunol. 10, 201-209 (2010).
145. Saito, Y. et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nature Biotech. 28, 275-280 (2010).
146. Hardingham, J. E. et al. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int. J. Cancer 89, 8-13 (2000).
147. Pantel, K. et al. Circulating epithelial cells in patients with benign colon diseases. Clin. Chem. 58, 936-940 (2012).
148. Rhim, A. D. et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology 146, 647-651 (2014).
149. Lindemann, F., Schlimok, G., Dirschedl, P., Witte, J. & Riethmuller, G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340, 685-689 (1992).
150. Putz, E. et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res. 59, 241-248 (1999).
151. Suzuki, M., Mose, E. S., Montel, V. & Tarin, D. Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am. J. Pathol. 169, 673-681 (2006).
152. Gil-Bernabe, A. M. et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 119, 3164-3175 (2012).
153. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Med. 18, 883-891 (2012).
154. Barkan, D. et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 70, 5706-5716 (2010).
155. Ding, L. & Morrison, S. J. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature 495, 231-235 (2013).
156. Bruns, I. et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nature Med. 20, 1315-1320 (2014).
157. Kunisaki, Y. et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 502, 637-643 (2013).
158. Kumar, M. E. et al. Mesenchymal cells. Defining a mesenchymal progenitor niche at single-cell resolution. Science 346, 1258810 (2014).